Anxo Pharmaceutical Co (ROCO:6677) Short-Term Debt: NT$326.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6677 Anxo Pharmaceutical Co Ltd ROCO:6677
56 GF Score
Price NT$16.10
GF Value NT$30.10
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Anxo Pharmaceutical Co Short-Term Debt?

Anxo Pharmaceutical Co ROCO:6677 -2.42% 56 Short-Term Debt is NT$326.6 Mil as of Dec. 2025. GuruFocus rates ROCO:6677 with a GF Score™ of 56/100 and a GF Value™ of NT$30.10 (Possible Value Trap). The stock has 4 warning signs investors should review.

Anxo Pharmaceutical Co's Short-Term Debt for the quarter that ended in Dec. 2025 was NT$326.6 Mil.

Anxo Pharmaceutical Co's quarterly Short-Term Debt increased from Dec. 2024 (NT$268.6 Mil) to Jun. 2025 (NT$281.8 Mil) and increased from Jun. 2025 (NT$281.8 Mil) to Dec. 2025 (NT$326.6 Mil).

Anxo Pharmaceutical Co's annual Short-Term Debt declined from Dec. 2023 (NT$273.5 Mil) to Dec. 2024 (NT$268.6 Mil) but then increased from Dec. 2024 (NT$268.6 Mil) to Dec. 2025 (NT$326.6 Mil).

Anxo Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Anxo Pharmaceutical Co Short-Term Debt Related Terms

Anxo Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Anxo Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anxo Pharmaceutical Co Short-Term Debt Chart

Anxo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 280.65 314.89 273.50 268.61 326.61

Anxo Pharmaceutical Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 273.50 248.83 268.61 281.77 326.61
ROCO:6677
56GF Score
Anxo Pharmaceutical Co Ltd ROCO:6677
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$326.6 Mil mean?
Anxo Pharmaceutical Co (ROCO:6677) has a Short-Term Debt of NT$326.6 Mil as of Dec. 2025.
Is Anxo Pharmaceutical Co's Short-Term Debt too high?
Anxo Pharmaceutical Co's current Short-Term Debt is NT$326.6 Mil. Overall, Anxo Pharmaceutical Co has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anxo Pharmaceutical Co's Short-Term Debt compare to ZTS?
Anxo Pharmaceutical Co's Short-Term Debt of NT$326.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Anxo Pharmaceutical Co's current Short-Term Debt is NT$326.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anxo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co (ROCO:6677) is currently considered Possible Value Trap. The stock's GF Value™ is NT$30.10, compared to a current price of NT$16.10 — trading 46.5% below its estimated fair value. The current Short-Term Debt is NT$326.6 Mil. Anxo Pharmaceutical Co's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Anxo Pharmaceutical Co (ROCO:6677), the current Short-Term Debt is NT$326.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anxo Pharmaceutical Co (ROCO:6677) Overvalued in 2026?

Based on GuruFocus' analysis, Anxo Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$16.10 is trading 46.5% below its estimated GF Value™ of NT$30.10. GuruFocus considers Anxo Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for ROCO:6677:

  • Short-Term Debt: NT$326.6 Mil
  • GF Value™: NT$30.10 vs. price of NT$16.10 (46.5% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6677 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anxo Pharmaceutical Co Business Description

Address 8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.
56GF Score

Get the complete analysis for ROCO:6677

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.10
Price
NT$30.10
GF Value